A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.

doi:10.1158/1078-0432.CCR-24-0605

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 13 Sept 2024

Grommes Christian, Nandakumar Subhiksha, Schaff Lauren R, Gavrilovic Igor, Kaley Thomas J, Nolan Craig P, Stone Jacqueline, Thomas Alissa A, Tang Sarah S, Wolfe Julia, Bozza Alexis, Wongchai Venissala, Hyde Alisson, Barrett Emma, Lynch Elizabeth A, Madzsar Juli T, Lin Andrew, Piotrowski Anna F, Pentsova Elena, Francis Jasmine H, Hatzoglou Vaios, Schultz Nikolaus, Reiner Anne S, Panageas Katherine S, DeAngelis Lisa M, Mellinghoff Ingo K

Abstract excerpt

PURPOSE: Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase. We previously reported the safety and short-term antitumor activity of ibrutinib in 20 patients with relapsed or refractory (r/r) primary central nervous system (CNS) lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL). PATIENTS AND METHODS: We enrolled 26 additional patients with r/r PCNSL/SCNSL into the dose-expansion cohort of the trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Agammaglobulinaemia Tyrosine Kinase

Share to Central Nervous System Neoplasms

Share to Lymphoma

Share to Neoplasm Recurrence, Local

Share to Piperidines

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 38995739
DOI: 10.1158/1078-0432.CCR-24-0605
PMCID: PMC11398981

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.PMID 38995739Read ↗

Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.Semantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.Semantic proximity Read ↗

CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experienceSemantic proximity Read ↗

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.Semantic proximity Read ↗

Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 StudySemantic proximity Read ↗

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaSemantic proximity Read ↗

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Semantic proximity Read ↗

Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi EraSemantic proximity Read ↗

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST studySemantic proximity Read ↗

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.Semantic proximity Read ↗

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.